Kirin

AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin

Retrieved on: 
Wednesday, August 5, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cars, Chemical compounds, Transport, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Kyowa Hakko Kirin, Tivozanib, Kirin, Chevrolet Aveo, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).
  • This milestone marks an important step forward for AVEOs non-oncology pipeline, said Michael Bailey, president and chief executive officer of AVEO.
  • We believe tivozanibs potential in non-oncology indications is significant, and we look forward to seeing Kyowa Kirin move this formulation into the clinic.
  • Under the terms of AVEOs agreement with Kyowa Kirin, in addition to the previously-paid upfront payment of $25 million to AVEO and waiver of AVEOs obligation to make an $18 million milestone payment upon AVEO gaining U.S. marketing approval of tivozanib for renal cell carcinoma, and now the IND development milestone, Kyowa Kirin has also agreed to pay AVEO up to an additional $388 million in potential milestone payments upon the successful achievement of certain development, regulatory, and commercial objectives in non-oncology indications of tivozanib.

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

Retrieved on: 
Monday, July 13, 2020
American football in Japan, Keio University, Minato, Tokyo, Kirin

Brings extensive experience in gut microbiota, a core area of interest for 4BIO

Key Points: 
  • Brings extensive experience in gut microbiota, a core area of interest for 4BIO
    LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB).
  • Professor Honda is a Professor in the Department of Microbiology and Immunology at Keio University School of Medicine, Tokyo, Japan.
  • Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: 4BIOs Scientific Advisory Board includes founders of the gene therapy field in both academic and hospital settings who lead groups in world centres of academic and clinical excellence.
  • Professor Hondas appointment builds on the recent appointment of Philippe Fauchet, OBE, as Venture Partner in Japan, and the strategic investment in 4BIO from Japanese Pharmaceutical company Kyowa Kirin.

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

Retrieved on: 
Monday, July 13, 2020
American football in Japan, Keio University, Minato, Tokyo, Kirin

Brings extensive experience in gut microbiota, a core area of interest for 4BIO

Key Points: 
  • Brings extensive experience in gut microbiota, a core area of interest for 4BIO
    LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB).
  • Professor Honda is a Professor in the Department of Microbiology and Immunology at Keio University School of Medicine, Tokyo, Japan.
  • Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: 4BIOs Scientific Advisory Board includes founders of the gene therapy field in both academic and hospital settings who lead groups in world centres of academic and clinical excellence.
  • Professor Hondas appointment builds on the recent appointment of Philippe Fauchet, OBE, as Venture Partner in Japan, and the strategic investment in 4BIO from Japanese Pharmaceutical company Kyowa Kirin.

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)

Retrieved on: 
Thursday, July 9, 2020
Life sciences, Articles, Biotechnology, Biosimilar, Drugs, Mylan, Fujifilm, Biopharmaceutical, Kirin, Food and Drug Administration

"The FDA approval of Hulio marks a significant milestone for both Fujifilm Kyowa Kirin Biologics and Mylan, increasing access to affordable treatment forU.S.

Key Points: 
  • "The FDA approval of Hulio marks a significant milestone for both Fujifilm Kyowa Kirin Biologics and Mylan, increasing access to affordable treatment forU.S.
  • Mylan and Fujifilm Kyowa Kirin Biologics entered into a partnership in 2018 for the commercialization of Hulio in Europe and Mylan has commercialized the product in severalcountries across the region.
  • In 2019, Mylan and Fujifilm Kyowa Kirin Biologics expanded the partnership globally.
  • Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; hereinafter "Fujifilm") and Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, hereinafter "Kyowa Kirin") on March 27, 2012 as a company for developing, manufacturing, and marketing biosimilars.

Kyowa Kirin Names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America

Retrieved on: 
Monday, June 29, 2020
Bastiani, Richard Posner, Kirin, Posner, Jurists, Philosophy, Legal professions

Most recently, Ms. Bastiani-Posner led the finance and IT functions as Senior Vice President, Finance Administration at the New York Genome Center, Inc.

Key Points: 
  • Most recently, Ms. Bastiani-Posner led the finance and IT functions as Senior Vice President, Finance Administration at the New York Genome Center, Inc.
  • "The North America region of Kyowa Kirin has the potential to grow substantially as we invest in our pipeline and our commercial portfolio," says Ms. Bastiani-Posner.
  • Ms. Bastiani-Posner succeeds Takeshi Masuda, who supported the finance team as an executive leader over the last several years with Kyowa Kirin.
  • "We are very pleased to have Ana Bastiani-Posner join our North America executive leadership team as Chief Financial Officer.

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin

Retrieved on: 
Monday, June 8, 2020
Kirin, Finance, Economy, Venture capital, Financial economics, Kirin Holdings

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.

Key Points: 
  • LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.
  • Kyowa Kirin is one of the largest pharmaceutical and biotechnology companies in Japan with a global presence and is the first strategic pharmaceutical investor in 4BIO Ventures II.
  • The investment will provide Kyowa Kirin with access to the advanced therapies space across the UK, Europe and the US through 4BIOs investment team, while Kyowa Kirin will provide 4BIO with access to its scientific and R&D teams to better inform its ongoing investment in the space.
  • Kieran Mudryy, Partner at 4BIO Capital, said: We welcome Kyowa Kirins investment in the 4BIO Ventures II fund as testament to Japanese interests in advanced therapies, and our ability to identify the most exciting developments in the area.

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin

Retrieved on: 
Monday, June 8, 2020
Kirin, Finance, Economy, Venture capital, Financial economics, Kirin Holdings

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.

Key Points: 
  • LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a leading Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, has made a strategic investment in 4BIOs Ventures II LP Fund.
  • Kyowa Kirin is one of the largest pharmaceutical and biotechnology companies in Japan with a global presence and is the first strategic pharmaceutical investor in 4BIO Ventures II.
  • The investment will provide Kyowa Kirin with access to the advanced therapies space across the UK, Europe and the US through 4BIOs investment team, while Kyowa Kirin will provide 4BIO with access to its scientific and R&D teams to better inform its ongoing investment in the space.
  • Kieran Mudryy, Partner at 4BIO Capital, said: We welcome Kyowa Kirins investment in the 4BIO Ventures II fund as testament to Japanese interests in advanced therapies, and our ability to identify the most exciting developments in the area.

MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

Retrieved on: 
Thursday, May 14, 2020
EHA, Kirin

The abstract is available on the EHA Annual Congress website .

Key Points: 
  • The abstract is available on the EHA Annual Congress website .
  • Presentations and posters will be available on the EHA website for on-demand viewing beginning on June 12, 2020at8:30 a.m.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.
  • You can learn more about the business of Kyowa Kirin at www.kyowakirin.com .

MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 7, 2020
Mei, Kirin

SAN DIEGO, May 7, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2020 and highlighted recent corporate progress.

Key Points: 
  • SAN DIEGO, May 7, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2020 and highlighted recent corporate progress.
  • In April 2020, the Company entered a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401.
  • MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.
    MEI to book U.S. sales on 50-50 profit and cost sharing.
  • As ofMarch 31, 2020, MEI had$92.8 millionin cash, cash equivalents and short-term investments, with no outstanding debt.

MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

Retrieved on: 
Tuesday, April 14, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Kirin, Companies, Kirin Company, the Global License, Development and Commercialization Agreement, ME-401, MEI Pharma, Kyowa Kirin

MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.

Key Points: 
  • MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.
  • "I am delighted to expand our agreement with MEI Pharma for the development and commercialization of ME-401 all over the world," said Tomohiro Sudo, Executive Officer, Director of Strategic Product Planning Department for Kyowa Kirin.
  • If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales.
  • Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401.